Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group.

Autor:	Takashima A; Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Ishiguro M; Health Science Research & Development Center, Tokyo Medical and Dental University, Tokyo, Japan., Sasaki K; Japan Clinical Oncology Group Data Center /Operations Office, National Cancer Center Hospital, Tokyo, Japan., Machida R; Japan Clinical Oncology Group Data Center /Operations Office, National Cancer Center Hospital, Tokyo, Japan., Nagashima F; Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan., Imaizumi J; Department of Gastroenterological Surgery, Gunma Prefectural Cancer Center, Gunma, Japan., Hamaguchi T; Department of Gastroenterological Oncology, Saitama Medical University International Medical Center, Saitama, Japan., Yamamoto Y; Department of Gastroenterology, University of Tsukuba Hospital, Tsukuba, Japan., Masuishi T; Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan., Asayama M; Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan., Ueno H; Department of Surgery, National Defense Medical College, Saitama, Japan., Shinozaki K; Division of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan., Kudo T; Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan., Machida N; Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan., Matsuoka H; Department of Surgery, Fujita Health University School of Medicine, Toyoake, Japan., Ishida H; Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan., Yamaguchi T; Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Osaka, Japan., Nogami H; Department of Surgery, Niigata Cancer Center Hospital, Niigata, Japan., Yamada T; Department of Gastroenterological Surgery, Nippon Medical School, Tokyo, Japan., Takegawa N; Department of Gastroenterology, Hyogo Cancer Center, Akashi, Hyogo, Japan., Kito Y; Department of Medical Oncology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan., Tonoike Y; Department of Medical Oncology, Nagaoka Chuo General Hospital, Niigata, Japan., Sawada R; Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan., Tsukamoto S; Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan., Kanemitsu Y; Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	Japanese journal of clinical oncology [Jpn J Clin Oncol] 2024 Oct 03; Vol. 54 (10), pp. 1107-1114.
DOI:	10.1093/jjco/hyae110
Abstrakt:	Background: Although treatment outcomes for metastatic colorectal cancer (mCRC) have dramatically improved over the past few decades, drug costs have also significantly increased. This study aimed to investigate which first-line treatment regimens for mCRC are actually used (frequency) in Japanese practice and at what cost. Methods: We collected data on patients with mCRC who received first-line treatment at 37 institutions of the Japan Clinical Oncology Group Colorectal Cancer Study Group from July 2021 to June 2022, and calculated the cost of regimens. The cost per month of each regimen was estimated based on standard usage, assuming a patient with a weight of 70 kg and a body surface area of 1.8 m2. We categorized the regimens into very high-cost (≥1 000 000 Japanese yen [JPY]/month), high-cost (≥500 000 JPY/month), and others (<500 000 JPY/month). Results: The study included 1880 participants, 24% of whom were ≥ 75 years. Molecular targeted containing regimens were received by 78% of the patients. The most frequently used regimen was the doublet regimen (fluoropyrimidine with either oxaliplatin or irinotecan) plus bevacizumab (43%), followed by doublet plus cetuximab or panitumumab (21%). The cost of molecular targeted drugs-containing regimens (ranging from 85 406 to 843 602 JPY/month) is much higher than that of only cytotoxic drug regimens (ranging from 17 672 to 51 004 JPY/month). About 16% received high-cost treatments that included panitumumab-containing regimens and pembrolizumab (17% of patients aged ≤74 years and 11% of patients aged ≥75 years). Conclusion: About 16% of mCRC patients received first-line treatment with regimens costing >500 000JPY/month, and molecular targeted drugs being the main drivers of cost. (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu